... Food and Drug Administration Highlights of Prescribing Information: Elrexfio — Pfizer Highlights of Prescribing Information: Lynozyfic — Regeneron Pharmaceuticals Highlights of Prescribing Information: Talvey — Janssen Pharmaceutical Companies What Do Clinical Trial Results Mean? ...
... This “off-the-shelf” approach means they’re available more quickly and are generally easier to get.Linvoseltamab-GcptApproved in July 2025 under the brand name Lynozyfic, linvoseltamab-gcpt is another bispecific T-cell engager that targets BCMA. ...
What Is BCMA-Targeted Immunotherapy? (VIDEO)
... This “off-the-shelf” approach means they’re available more quickly and are generally easier to get.Linvoseltamab-GcptApproved in July 2025 under the brand name Lynozyfic, linvoseltamab-gcpt is another bispecific T-cell engager that targets BCMA. ...
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
Can Multiple Myeloma Be Cured? Advances in Research and Survival
... Examples include elranatamab (Elrexfio), teclistamab (Tecvayli), talquetamab (Talvey), and linvoseltamab-gcpt (Lynozyfic). Nuclear export inhibitors — These drugs block XPO1, a protein that helps cancer cells survive. Selinexor (Xpovio) is the first FDA-approved XPO1 inhibitor, preventing this process and causing cancer cell death. ...
... Food and Drug Administration (FDA) in 2022, and talquetamab (Talvey, approved in 2023) Elranatamab-bcmm (Elrexfio), a bispecific antibody approved in 2023, and linvoseltamab-gcpt (Lynozyfic, approved in 2025) Monoclonal antibodies like daratumumab It’s important to take care of your body while living with RRMM and going through cancer treatments. ...
What Is the Life Expectancy With Relapsed/Refractory Myeloma?
... Food and Drug Administration (FDA) in 2022, and talquetamab (Talvey, approved in 2023) Elranatamab-bcmm (Elrexfio), a bispecific antibody approved in 2023, and linvoseltamab-gcpt (Lynozyfic, approved in 2025) Monoclonal antibodies like daratumumab It’s important to take care of your body while living with RRMM and going through cancer treatments. ...
... Linvoseltamab-gcpt (Lynozyfic) is a newer BCMA-directed T-cell engager. Elranatamab-bcmm (Elrexfio) is another BCMA-directed CD3 T-cell engager. Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. ...
Relapsed vs. Refractory: What It Means in Multiple Myeloma
... Linvoseltamab-gcpt (Lynozyfic) is a newer BCMA-directed T-cell engager. Elranatamab-bcmm (Elrexfio) is another BCMA-directed CD3 T-cell engager. Talquetamab-tgvs (Talvey) is a bispecific T-cell engager that targets GPRC5D, another protein found on myeloma cells, and CD3 on T cells. ...
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
Myeloma Treatment Journey: From First Line to Fourth Line
... These treatments can also cause CRS and other side effects, so close monitoring is necessary during the first few doses.Bispecific antibodies used to treat myeloma include: Elranatamab-bcmm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab-tgvs (Talvey) Teclistamab-cqyv (Tecvayli) Antibody-Drug ConjugateAnother immunotherapy your doctor may recommend ...
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
8 Refractory Myeloma Therapies: Know Your Treatment Options
... The FDA granted the drug accelerated approval due to its performance in clinical studies.Since then, the FDA has approved three new BiTES: Elranatamab-bccm (Elrexfio) Linvoseltamab-gcpt (Lynozyfic) Talquetamab (Talvey) Read more about bispecific T-cell engagers and how they work to treat relapsed or refractory multiple myeloma.6. ...
... In 2025, the FDA approved linvoseltamab-gcpt (Lynozyfic) for adults with RRMM who have received four or more prior lines of treatment.BiTEs work by targeting BCMA and the CD3 protein found in T cells. ...
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
Myeloma Treatments: Risks and Benefits
... As of July 2025, four bispecific antibodies — elranatamab-bcmm (Elrexfio), talquetamab (Talvey), teclistamab-cqyv (Tecvayli), and linvoseltamab-gcpt (Lynozyfic) — have been approved for myeloma. ...
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
12 Myeloma Treatment Options
... As a result, teclistamab-cqyv causes tumor-cell lysis (destruction).Other bispecific T-cell engagers sometimes used to treat myeloma are talquetamab-tgvs (Talvey), elranatamab-bcmm (Elrexfio), and linvoseltamab-gcpt (Lynozyfic).6. Targeted TherapiesTargeted therapies limit how much cancer cells can divide, multiply, and spread. ...
Join
Your Privacy Choices
